Advertisement

Drugs & Therapy Perspectives

, Volume 34, Issue 5, pp 223–230 | Cite as

Assessment of the risk of acute kidney injury associated with the use of pantoprazole and esomeprazole

  • K. Renuka Prasad
  • Priyanka Chettri
  • N. A. Rajesh
  • A. Rathinaswamy
  • R. Padmanaban
  • T. M. Vijayakumar
Original Research Article
  • 148 Downloads

Abstract

Background

Many recent observational studies suggest that there is an association between the use of proton pump inhibitors (PPIs) and kidney disease, but no studies comparing the relative risk between PPIs have been conducted. Hence, we designed a study to evaluate the risk of acute kidney injury (AKI) associated with the use of pantoprazole and esomeprazole.

Methods

This cross-sectional pilot study included 52 pantoprazole users, 51 esomeprazole users and 50 non-PPI users. Biochemical parameters, such as urea, creatinine, sodium, potassium, chloride, bicarbonate, calcium, magnesium, phosphorus, and urine neutrophil gelatinase-associated lipocalin (NGAL) levels were determined to estimate the risk of AKI. Relative to non-exposure to PPIs, the use of pantoprazole increased the risk of AKI, as did the use of esomeprazole.

Results

Serum magnesium values were inversely correlated with the NGAL levels in the pantoprazole and esomeprazole group, but not in the non-exposed group.

Conclusion

Our study reveals that the use of pantoprazole and esomeprazole are both associated with an increased risk of AKI.

Notes

Acknowledgements

We would like to thank Prof. K. S. Lakshmi, Dean, SRM College of Pharmacy, for her kind support throughout the study. The authors would also like to thank all subjects, nurses, doctors, and research assistants who have contributed to this research.

Compliance with ethical standards

Conflict of interest

All authors declare no competing interests.

Funding

Financial support was provided by the SRM Institute of Science and Technology, Kattankulathur, India.

Ethical consideration

The study was conducted according to the standards of the International Committee on Harmonization on Good Clinical Practice and the revised version of the Declaration of Helsinki. This study protocol was approved by the institutional human ethics committee of SRM Medical College Hospital and Research Centre (Permission No. 1062/IEC/2016).

References

  1. 1.
    Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10:528–34.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Li Z, Wu C, Li L, et al. Effect of long-term proton pump inhibitor administration on gastric mucosal atrophy: a meta-analysis. Saudi J Gastroenterol. 2017;23:222–8.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Avinash A, Patil N, Kunder SK, et al. A retrospective study to assess the effect of proton pump inhibitors on renal profile in a south Indian hospital. J Clin Diagn Res. 2017;11:FC09–12.  https://doi.org/10.7860/jcdr/2017/26097.9752.PubMedPubMedCentralGoogle Scholar
  4. 4.
    DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux. Am J Gastroenterol. 2005;100:190–200.CrossRefPubMedGoogle Scholar
  5. 5.
    Katz MH. Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users. Arch Intern Med. 2010;170:747–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Gastroenterol. 2009;122(10):896–903.Google Scholar
  7. 7.
    Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017;11:27–37.CrossRefPubMedGoogle Scholar
  8. 8.
    Parikh N, Howden CW. The safety of drugs used in acid-related disorders and functional gastrointestinal disorders. Gastroenterol Clin North Am. 2010;39(3):529–42.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Myers RP, McLaughlin K, Hollomby DJ. Acute interstitial nephritis due to omeprazole. Am J Gastroenterol. 2001;96:3428–31.CrossRefPubMedGoogle Scholar
  10. 10.
    Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011;56:931–50.CrossRefPubMedGoogle Scholar
  11. 11.
    Metz DC. Long-term use of proton-pump inhibitor therapy. Gastroenterol Hepatol. 2008;4:322–5.Google Scholar
  12. 12.
    Praga M, González E. Acute interstitial nephritis. Kidney Int. 2010;77:956–61.CrossRefPubMedGoogle Scholar
  13. 13.
    Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat Rev Nephrol. 2010;6:461–70.CrossRefPubMedGoogle Scholar
  14. 14.
    Ten RM, Torres VE, Milliner DS, et al. Acute interstitial nephritis: immunologic and clinical aspects. Mayo Clin Proc. 1988;63:921–30.CrossRefPubMedGoogle Scholar
  15. 15.
    Antoniou T, Macdonald EM, Hollands S, et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. CMAJ Open. 2015;3:E166–71.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: a nested case-control study. BMC Nephrol. 2013;14:150.  https://doi.org/10.1186/1471-2369-14-150.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Int Med. 2016;176:238–46.CrossRefGoogle Scholar
  18. 18.
    Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19(1):25–35.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Shin JM, Cho YM, Sachs G. Chemistry of covalent inhibition of the gastric (H + , K +)-ATPase by proton pump inhibitors. J Am Chem Soc. 2004;126(25):7800–11.CrossRefPubMedGoogle Scholar
  20. 20.
    Asano S, Yoshida A, Yashiro H, et al. The cavity structure for docking the K(+)-competitive inhibitors in the gastric proton pump. J Biol Chem. 2004;279:13968–75.CrossRefPubMedGoogle Scholar
  21. 21.
    Jin R, Grunkemeier GL, Brown JR. Estimated glomerular filtration rate and renal function. Ann Thorac Surg. 2008;86:1–3.  https://doi.org/10.1016/j.athoracsur.2008.05.007.CrossRefPubMedGoogle Scholar
  22. 22.
    National Clinical Guideline Centre. National Institute for Health and Clinical Excellence Guidance: acute kidney injury: prevention, detection and management up to the point of renal replacement therapy. London: Royal College of Physicians (UK) National Clinical Guideline Centre; 2013. https://www.ncbi.nlm.nih.gov/pubmed/25340231. Accessed on 3rd April 2017.
  23. 23.
    Arora P, Gupta A, Golzy M, et al. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. BMC Nephrol. 2016;17(1):112.  https://doi.org/10.1186/s12882-016-0325-4.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Brewster UC, Perazella MA. Proton pump inhibitors and the kidney: critical review. Clin Nephrol. 2007;68:65–72.CrossRefPubMedGoogle Scholar
  25. 25.
    Kim SY, Moon A. Drug-induced nephrotoxicity and its biomarkers. Biomol Ther (Seoul). 2012;20:268–72.CrossRefGoogle Scholar
  26. 26.
    Brewster UC, Perazella MA. Acute kidney injury following proton pump inhibitor therapy. Kidney Int. 2007;71(6):589–93.CrossRefPubMedGoogle Scholar
  27. 27.
    Rossert J. Drug-induced acute interstitial nephritis. Kidney Int. 2001;60(2):804–17.CrossRefPubMedGoogle Scholar
  28. 28.
    Raghavan R, Shawar S. Mechanisms of drug-induced interstitial nephritis. Adv Chronic Kidney Dis. 2017;24:64–71.CrossRefPubMedGoogle Scholar
  29. 29.
    Naughton CA. Drug-induced nephrotoxicity. Am Fam Phys. 2008;78:743–50.Google Scholar
  30. 30.
    O’Neill LW, Culpepper BL, Galdo JA. Long-term consequences of chronic proton pump inhibitor use. US Pharm. 2013;38(12):38–42.Google Scholar
  31. 31.
    Härmark L, van der Wiel HE, de Groot MCH, et al. Proton pump inhibitor-induced acute interstitial nephritis. Br J Clin Pharmacol. 2007;64:819–23.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Peng YC, Lin CL, Yeh HZ, et al. Association between the use of proton pump inhibitors and the risk of ESRD in renal diseases: a population-based, case-control study. Medicine. 2016;95:e3363.  https://doi.org/10.1097/MD.0000000000003363.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Ozkan S, Durukan P, Kavalci C, et al. Importance of neutrophil gelatinase-associated lipocalin in differential diagnosis of acute and chronic renal failure. Iranian Red Cres Med J. 2014;16:e14133.  https://doi.org/10.5812/ircmj.14133.Google Scholar
  34. 34.
    Lippi G, Aloe R, Storelli A, et al. Evaluation of NGAL Test, a fully-automated neutrophil gelatinase-associated lipocalin (NGAL) immunoassay on Beckman Coulter AU 5822. Clin Chem Lab Med. 2011;50:1581–4.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pharmacy Practice, SRM College of PharmacySRM Institute of Science and TechnologyChennaiIndia
  2. 2.Department of Medical Gastroenterology, SRM Medical College Hospital and Research CentreSRM Institute of Science and TechnologyChennaiIndia
  3. 3.Department of Surgical Gastroenterology, SRM Medical College Hospital and Research CentreSRM Institute of Science and TechnologyChennaiIndia
  4. 4.Department of Nephrology, SRM Medical College Hospital and Research CentreSRM Institute of Science and TechnologyChennaiIndia

Personalised recommendations